8-K: Checkpoint Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Checkpoint Therapeutics reported its second quarter 2024 financial results, provided a corporate update, and announced the resubmission of its Biologics License Application (BLA) for cosibelimab.

Summary

• Checkpoint Therapeutics announced its second quarter 2024 financial results, with a net loss of $6.7 million, or $0.18 per share, compared to a net loss of $16.5 million, or $1.05 per share, in the same quarter of 2023.
• The company's cash and cash equivalents totaled $5.0 million as of June 30, 2024, compared to $11.2 million at March 31, 2024, and $4.9 million at December 31, 2023.
• Research and development expenses for the second quarter of 2024 were $4.5 million, a decrease from $13.9 million in the second quarter of 2023.
• General and administrative expenses for the second quarter of 2024 were $2.2 million, slightly down from $2.3 million in the same quarter of 2023.
• Checkpoint resubmitted its BLA for cosibelimab after reaching alignment with the FDA on its resubmission strategy, and the FDA has set a PDUFA goal date of December 28, 2024.
• The company also completed a registered direct offering and private placement in July 2024, raising approximately $12.0 million in gross proceeds.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the resubmission of the BLA and improved financial results, but there are still risks associated with regulatory approval and the company's financial position.

Positives

• The resubmission of the BLA for cosibelimab was accepted by the FDA, indicating progress towards potential approval.
• The company reached alignment with the FDA on its resubmission strategy, suggesting a clear path forward.
• The decrease in research and development expenses indicates improved cost management.
• The net loss decreased significantly year-over-year, showing improved financial performance.
• The company successfully raised $12.0 million in gross proceeds through a registered direct offering and private placement.

Negatives

• The company's cash position decreased to $5.0 million as of June 30, 2024, indicating a need for additional funding.
• The company experienced a net loss of $6.7 million for the second quarter of 2024, although this was an improvement year-over-year.
• The initial BLA for cosibelimab received a Complete Response Letter (CRL) from the FDA, requiring a resubmission.

Risks

• The regulatory review process for cosibelimab is subject to risks and uncertainties, and there is no guarantee of approval.
• The company's third-party contract manufacturing organization (CMO) must adequately address issues raised in the CRL to ensure approval.
• The company is dependent on third-party suppliers and may face risks related to their performance.
• Checkpoint Therapeutics requires substantial additional funds to continue operations and development programs.
• The company faces competition in the oncology market, which could impact the commercial success of cosibelimab.

Future Outlook

The company is focused on working with the FDA to secure approval for cosibelimab, with a PDUFA goal date of December 28, 2024. They are also exploring the combined therapeutic potential of cosibelimab with other therapies and continuing the development of olafertinib.

Management Comments

• James F. Oliviero, President and Chief Executive Officer of Checkpoint, stated that they have made significant recent progress in seeking approval for cosibelimab.
• Oliviero also mentioned that they are pleased to have reached alignment with the FDA on their strategy to address the deficiencies identified in the CRL.

Industry Context

This announcement is relevant to the broader oncology and immunotherapy industry, as Checkpoint Therapeutics is developing novel treatments for solid tumor cancers. The progress of cosibelimab is being closely watched as it represents a potential new treatment option for patients with metastatic or locally advanced cutaneous squamous cell carcinoma.

Comparison to Industry Standards

• Checkpoint's focus on anti-PD-L1 antibodies like cosibelimab aligns with the industry trend of developing immune checkpoint inhibitors for cancer treatment.
• The company's approach to addressing the FDA's CRL by resubmitting the BLA is a standard process in the pharmaceutical industry.
• The collaboration to explore the combined therapeutic potential of cosibelimab with GC Cells Immuncell-LC is an example of the industry's move towards combination therapies to enhance efficacy.
• Companies like Regeneron and Sanofi with their Libtayo (cemiplimab) are direct competitors in the cSCC space, and the success of cosibelimab will be measured against the efficacy and safety of these existing treatments.
• The financial results, particularly the decrease in R&D expenses and net loss, will be compared to other clinical-stage biotech companies of similar size and focus.

Related Party Transactions

• The company reported revenue from related parties of $41,000 for the three months ended June 30, 2024, and $41,000 for the six months ended June 30, 2024.
• The company reported accounts payable and accrued expenses related party of $3,179,000 as of June 30, 2024.

Stakeholder Impact

• Shareholders may be positively impacted by the progress of cosibelimab and the improved financial results.
• Patients with metastatic or locally advanced cSCC may benefit from a new treatment option if cosibelimab is approved.
• Employees may be impacted by the company's financial performance and the success of its development programs.
• Suppliers and creditors may be impacted by the company's ability to secure additional funding and achieve its milestones.

Next Steps

• Checkpoint will work with the FDA in advance of the PDUFA goal date of December 28, 2024, to potentially deliver cosibelimab to patients.
• The company will continue to explore the combined therapeutic potential of cosibelimab with other therapies.
• Checkpoint will continue the development of olafertinib, its lead small-molecule, targeted anti-cancer agent.

Key Dates

Keywords

cosibelimab, FDA, BLA, cutaneous squamous cell carcinoma, cSCC, oncology, immunotherapy, PDUFA, clinical-stage, checkpoint therapeutics